欧盟委员会批准BALVERSA (erdafitinib),这是第一个泛FGFR激酶抑制剂,用于转移性尿路细胞癌患者. European Commission approves BALVERSA (erdafitinib), the first pan-FGFR kinase inhibitor, for metastatic urothelial carcinoma patients.

欧洲委员会批准BALVERSA(erdafitinib),这是第一Pan-FGFR脂酶抑制剂,用于至少拥有1 PD-1/PD-L1抑制剂的具有转移性极地癌肿瘤的成年人。 European Commission approves BALVERSA (erdafitinib), the 1st pan-FGFR kinase inhibitor, for adults with metastatic urothelial carcinoma who've had at least 1 PD-1/PD-L1 inhibitor. 根据THOR的研究批准,该研究显示,使用ERdafitinib与化疗的致死风险降低了36%,对ERdafitinib病人而言,总存活率中位数超过1年。 Approval based on THOR study, which showed a 36% reduced risk of death with erdafitinib vs chemotherapy, with a median overall survival of over 1 year for erdafitinib patients. 这标志着转移性膀胱癌患者的重大进步,这种癌症是欧洲常见的癌症类型,对创新治疗的需求高度未得到满足。 This marks a significant advancement for patients with metastatic bladder cancer, a common cancer type in Europe with high unmet need for innovative treatments.